Literature DB >> 3494670

OKT3-activated locomotion of human blood lymphocytes: a phenomenon requiring contact of T cells with Fc receptor-bearing cells.

P C Wilkinson, A Higgins.   

Abstract

The OKT3 antibody activates locomotion of human blood T lymphocytes as measured by polarization assays and invasion of collagen gels. The proportion of motile cells increases during a period of 24-48 hr of culture, even following only a brief initial contact with OKT3. The motile cells are the growing population. Locomotion activation is cell-density dependent. Studies with surface-bound mitogens, namely substratum-bound OKT3 and Con A-Sepharose, showed that only lymphocytes in direct contact with the mitogen acquired locomotor capacity. Those separated from it by a cell-impermeable filter were not activated. The response to OKT3 requires the whole antibody molecule. F(ab')2 fragments were inactive. Intact normal human IgG, but not its F(ab')2 fragments, blocked the response. Removal of RFc gamma + cells from the population by rosetting with IgG-Ab-coated sheep red cells prevented the response. These findings suggest that an RFc gamma + population has to be present for T cells to become activated to locomotion by OKT3, and that the OKT3 antibody links the T cell to an FcR+ cell, cell-to-cell contact being essential for activating the locomotor response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494670      PMCID: PMC1453260     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

1.  Human T-lymphocyte chemotactic activity: nature and production in response to antigen.

Authors:  J W Potter; D E Van Epps
Journal:  Cell Immunol       Date:  1986-01       Impact factor: 4.868

2.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

Authors:  T W Chang; P C Kung; S P Gingras; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

3.  Cellular origin and interactions involved in gamma-interferon production induced by OKt3 monoclonal antibody.

Authors:  T W Chang; D Testa; P C Kung; L Perry; H J Dreskin; G Goldstein
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

4.  Invasion of collagen gels by mouse lymphoid cells.

Authors:  J M Shields; W Haston; P C Wilkinson
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

5.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

Review 6.  Lymphocyte locomotion and migration.

Authors:  D M Parrott; P C Wilkinson
Journal:  Prog Allergy       Date:  1981

7.  Induction of human T lymphocyte motility by interleukin 2.

Authors:  H Kornfeld; J S Berman; D J Beer; D M Center
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Lymphocyte locomotion and attachment on two-dimensional surfaces and in three-dimensional matrices.

Authors:  W S Haston; J M Shields; P C Wilkinson
Journal:  J Cell Biol       Date:  1982-03       Impact factor: 10.539

9.  Antigen-induced locomotor responses in lymphocytes.

Authors:  P C Wilkinson; D M Parrott; R J Russell; F Sless
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.

Authors:  K Welte; M Andreeff; E Platzer; K Holloway; B Y Rubin; M A Moore; R Mertelsmann
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  13 in total

1.  The bacterial superantigen Staphylococcal enterotoxin B stimulates lymphocyte locomotor capacity during culture in vitro.

Authors:  I Newman; P C Wilkinson
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  Relation between locomotion, chemotaxis and clustering of immune cells.

Authors:  P C Wilkinson
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

3.  The interaction of activated integrin lymphocyte function-associated antigen 1 with ligand intercellular adhesion molecule 1 induces activation and redistribution of focal adhesion kinase and proline-rich tyrosine kinase 2 in T lymphocytes.

Authors:  J L Rodríguez-Fernández; M Gómez; A Luque; N Hogg; F Sánchez-Madrid; C Cabañas
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

4.  Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission.

Authors:  J Deschambeault; J P Lalonde; G Cervantes-Acosta; R Lodge; E A Cohen; G Lemay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Recombinant IL-4 and IFN-gamma activate locomotor capacity in human B lymphocytes.

Authors:  P C Wilkinson; L N Islam
Journal:  Immunology       Date:  1989-06       Impact factor: 7.397

6.  FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes.

Authors:  P C Wilkinson; E A Watson
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

7.  Cyclosporin A inhibits mitogen-activated but not phorbol ester-activated locomotion of human lymphocytes.

Authors:  P C Wilkinson; A Higgins
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

8.  Locomotor responses of human CD45 lymphocyte subsets: preferential locomotion of CD45RO+ lymphocytes in response to attractants and mitogens.

Authors:  I Newman; P C Wilkinson
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

9.  Role of the cytoskeleton in cell-to-cell transmission of human immunodeficiency virus.

Authors:  R Pearce-Pratt; D Malamud; D M Phillips
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  The defect of lymphocyte locomotion in chronic lymphocytic leukaemia: studies of polarization and growth-dependent locomotion.

Authors:  P C Wilkinson; L N Islam; D Sinclair; J H Dagg
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.